Replies to post #274803 on Amarin Corp Plc (AMRN)

[louieblouie]

https://en.wikipedia.org/wiki/Biotechnology_Innovation_Organization

https://www.bio.org

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Corporate members range from entrepreneurial companies developing a first product to Fortune 500 multinationals. We also represent state and regional biotech associations, service providers to the industry, and academic centers. Our members help foster a healthy economy by creating good-paying, biotechnology jobs. We also host the largest cost-savings program in the life sciences industry, BIO Business Solutions, which saved $430 million in aggregate for 3,700+ companies last year.

BIO also works towards enriching the industry with networking, partnering and education opportunities. We organize the BIO International Convention, the global event for biotechnology, along with many other industry-leading investor and partnering events held around the world. Arguably the industry’s leading partnering software, BIO One-on-One Partnering™ facilitates 50,000 face-to-face meetings each year among investors, biotechs, pharmaceutical companies, academic institutions and non-profits at live events.

To advocate for our industry, BIO is organized into four different sections to best represent our members and their goals:

about-page-emerging-Image
Emerging Biotech Companies
We serve the needs of small-to-medium size companies, most of whom do not yet have major products approved and on the market. Whether advocating for pro-innovation tax policies to encouraging an economic and policy environment to foster biotech investment, we focus on critical issues affecting smaller companies and build programs to enhance their development.

Health Biotechnology
We promote biomedical innovation by developing and advocating for public policies that represent the best interests of members focused on human health. We break-down the barriers that impede American innovation by reducing bureaucratic hurdles to lifesaving technologies. Among the priority issues are matters affecting the healthcare-related regulatory and reimbursement climate, pandemic and biodefense preparedness, publicly funded scientific research, and personalized medicine.

About-Page-health_Image
about-page-IandE-Image
Industrial & Environmental Biotechnology
We promote the use of industrial enzymes, conversion of biomass to energy and chemicals, and innovative clean up technologies. We work closely with the U.S. Congress, federal agencies, and international organizations to encourage the development of technologies that make our lives and environment cleaner, safer and healthier.

Food & Agriculture Biotechnology
We create and advance industry policies on all food and agriculture biotechnology issues related to international affairs, government relations, science and regulatory affairs, and media and public affairs. We work for a safe and clean supply of healthy food for a growing global population.

About-Page-FoodAg_Image

[louieblouie]

https://aimedalliance.org

MISSION, VISION, BELIEFS


Mission

Aimed Alliance is a 501(c)(3) not-for-profit health policy organization. The mission of Aimed Alliance is to protect and enhance the rights of health care consumers and providers.

Vision

The vision of Aimed Alliance is a society in which consumers, in consultation with their health care providers and loved ones, can make informed and individually appropriate decisions about their health care, and those decisions are not overridden by third parties.

Beliefs

We believe that Americans should value their health care and prioritize it as consumers.

We believe that health care industry stakeholders should place the health and safety of patients above all other considerations.

We believe that the costs of health care services should be reasonable and transparent.



Activities

Aimed Alliance advances its mission by:

Supporting laws, regulations, and policies that encourage or require health care to be accessible, culturally competent, efficient, ethical, safe, and transparent.

Acting with urgency to curtail the use of discriminatory practices in the delivery of health care and the administration of health insurance and employee benefits.

Encouraging the adoption of innovative health care products, services, and benefit designs.

Supporting a coalition of like-minded, consumer-focused organizations that aims to improve access to individualized treatment.

Conducting research and analysis and translating our findings into economically sound and actionable insights for health care stakeholders to improve the United States health care system.

Distributing educational resources on health care issues to foster public understanding and engagement.

[louieblouie]

[ggwpq]

HDG, according to Graham v. John Deere four factors:

(1) the scope and content of the prior art; (2) the differences between the prior art and the patent claims; (3) the level of ordinary skill; and (4) secondary considerations

Regarding factor number 2, differences between the prior art and the patent claims, prior arts in this case are all HTG or average TG while patent claims are VHTG. Since the MARINE patents are assumed valid going into Du's trial, the defendants need to explain why the HTG and VHTG effect on LDL-C should be the same between the two groups in order to satisfy Graham number 2. Based on what you read in Du's bench order, did the defendants accomplish that?

TIA.